Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1CNS 1

Conditions

Neoplasms 2Sarcoma, Ewing 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Bone Neoplasms 1

Interventions

Ibandronic Acid 8Gemcitabine 8Doxorubicin 6Cyclophosphamide 6Zoledronic Acid 5Radiation 4Nivolumab 4Irinotecan 4pembrolizumab 3Vincristine 3Temozolomide 3Magnetic Resonance Spectroscopy 3Ipilimumab 3Docetaxel 3Cisplatin 33-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 3regorafenib 2pegfilgrastim 2Tranexamic Acid 2Trabectedin 2Sunitinib 2Standard of Care 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2Radiosurgery 2Proton Therapy 2Methotrexate 2Injections 2Ifosfamide 2Everolimus 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Bone Neoplasms × robatumumab × Clear all
NCT00960063 2018-08-27

A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006)

Merck Sharp & Dohme LLC

Phase 1 Terminated
4 enrolled 8 charts
CNSGenitourinarySarcoma

Bone Neoplasms, Carcinoma, Renal Cell, Neoplasms, Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡